Study ID: ECOG E2408

3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma


This study will evaluate two new treatment approaches. Participants in this study have untreated ┬┐high risk┬┐ follicular lymphoma. The purpose of this study is to try and improve the outcomes for patients with this diagnosis. These new treatment agents will be added to standard Bendamustine-Rituximab (BR) induction therapy (given first) and to standard rituximab continuation therapy (following induction therapy). The purpose of making these additions to standard therapy is to see if induction therapy and/or continuation therapy can improve outcomes (i.e. longer remission and possibly improved overall survival). The study also wants to monitor any side effects from these treatments and see if they are tolerable.

Bemidji Clinic, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD
NHL (Non-Hodgkins Lymphoma)
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list